Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357352 · ClinicalTrials.gov registry record
Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
A clinical trial of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis, sponsored by Methodist Health System.
- Completed
- Registry status
- 263
- Enrollment target
- 1
- Study location
NCT05357352 is a study of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis that has completed, run by Methodist Health System. The registered enrollment target is 263 participants, above the 185-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (42% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05357352, a study of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis, has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 263 participants
- Enrollment target
- 1
- Study location
Study Summary
Few studies have evaluated an extensive list of possible risk factors for NAFLD for their association with presence and severity of histologic features. We wish to conduct a retrospective study on these possible factors (including demographics, comorbid diseases, and medications) for their association, if any, with severity of histopathologic findings. This study hypothesize that certain risk factors, specifically those contributing to or consisting of metabolic syndrome, will have higher NASH Fibrosis stages.
Conditions Studied
Interventions
- OTHER NAFLD/NASH
Study Locations (1)
Texas
- Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2019-05-24 |
| Est. Completion | 2021-04-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05357352
The ClinicalTrials.gov registry entry for NCT05357352 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 185-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (42% higher). The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which NAFLD/NASH is the first listed.
NCT05357352 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05357352 about?
NCT05357352 is a clinical study titled "Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis". Few studies have evaluated an extensive list of possible risk factors for NAFLD for their association with presence and severity of histologic features. We wish to conduct a retrospective study on these possible factors (including demographics, comorbid diseases, and medications) for their associati...
What is the current status of trial NCT05357352?
This trial is currently completed. The enrollment target is 263 participants. The study started on 2019-05-24. Estimated completion is 2021-04-07.
What conditions does trial NCT05357352 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis.
What interventions are being tested in trial NCT05357352?
The interventions under investigation include: NAFLD/NASH (OTHER).
Who is sponsoring clinical trial NCT05357352?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05357352 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
RECRUITING · Phase 3
-
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RECRUITING · Phase 3
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
-
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
RECRUITING · NA
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
RECRUITING
-
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.